Abstract:CCR5, a chemokine receptor central for orchestrating lymphocyte/cell migration to the sites of inflammation and to the immunosurveillance, is involved in the pathogenesis of a wide spectrum of health conditions, including inflammatory diseases, viral infections, cancers and autoimmune diseases. CCR5 is also the primary coreceptor for the human immunodeficiency viruses (HIVs), supporting its entry into CD4 + T lymphocytes upon transmission and in the early stages of infection in humans. A natural loss-of-function mutation CCR5-Δ32, preventing the mutated protein expression on the cell surface, renders homozygous carriers of the null allele resistant to HIV-1 infection. This phenomenon was leveraged in the development of therapies and cure strategies for AIDS. Meanwhile, over 40 African nonhuman primate species are long-term hosts of simian immunodeficiency virus (SIV), an ancestral family of viruses that give rise to the pandemic CCR5 (R5)-tropic HIV-1. Many natural hosts typically do not progress to immunodeficiency upon the SIV infection. They have developed various strategies to minimize the SIV-related pathogenesis and disease progression, including an array of mechanisms employing modulation of the CCR5 receptor activity: (i) deletion mutations abrogating the CCR5 surface expression and conferring resistance to infection in null homozygotes; (ii) downregulation of CCR5 expression on CD4 + T cells, particularly memory cells and cells at the mucosal sites, preventing SIV from infecting and killing cells important for the maintenance of immune homeostasis, (iii) delayed onset of CCR5 expression on the CD4 + T cells during ontogenetic development that protects the offspring from vertical transmission of the virus. These host adaptations, aimed at lowering the availability of target CCR5 + CD4 + T cells through CCR5 downregulation, were countered by SIV, which evolved to alter the entry coreceptor usage toward infecting different CD4 + T-cell subpopulations that support viral replication yet without disruption of host immune homeostasis. These natural strategies against SIV/HIV-1 infection, involving control of CCR5 function, inspired therapeutic approaches against HIV-1 disease, employing CCR5 coreceptor blocking as well as gene editing and silencing of CCR5. Given the pleiotropic role of CCR5 in health beyond immune disease, the precision as well as costs and benefits of such interventions needs to be carefully considered.

HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5

Genome Editing of CXCR4 by CRISPR/cas9 Confers Cells Resistant to HIV-1 Infection.

Regulation of Human Immunodeficiency Virus Type 1 Infection, Β-Chemokine Production, and CCR5 Expression in CD40L-Stimulated Macrophages: Immune Control of Viral Entry

Chemokine Receptor Ccr5 Functionally Couples to Inhibitory G Proteins and Undergoes Desensitization

CCR5 as a Coreceptor for Human Immunodeficiency Virus and Simian Immunodeficiency Viruses: A Prototypic Love-Hate Affair

Chemokine Coreceptor Usage by Diverse Primary Isolates of Human Immunodeficiency Virus Type 1.

Envelope Glycoproteins from Human Immunodeficiency Virus Types 1 and 2 and Simian Immunodeficiency Virus Can Use Human CCR5 As a Coreceptor for Viral Entry and Make Direct CD4-dependent Interactions with This Chemokine Receptor

Coreceptor Usage of Primary Human Immunodeficiency Virus Type 1 Isolates Varies According to Biological Phenotype

Identification of a Major Co-Receptor for Primary Isolates of HIV-1

Stoichiometry for entry and binding properties of the Env protein of R5 T cell-tropic HIV-1 and its evolutionary variant of macrophage-tropic HIV-1

Identification of Preferential CD4+ T-cell Targets for HIV Infection in the Cervix

In Vivo Evolution of HIV-1 Co-Receptor Usage and Sensitivity to Chemokine-Mediated Suppression.

Antibodies to Several Conformation-Dependent Epitopes of Gp120/gp41 Inhibit CCR-5-dependent Cell-to-cell Fusion Mediated by the Native Envelope Glycoprotein of a Primary Macrophage-Tropic HIV-1 Isolate

The Membrane-Proximal Region of C–C Chemokine Receptor Type 5 Participates in the Infection of HIV-1

Quantifying the Sensitivity of HIV-1 Viral Entry to Receptor and Coreceptor Expression

Transmission of highly virulent CXCR4 tropic HIV-1 through the mucosal route in an individual with a wild-type CCR5 genotype

Expression cloning of new receptors used by simian and human immunodeficiency viruses

124 CCR6 Ligands Inhibit HIV in Highly Susceptible CD4+CCR6+ T Cells by Inducing APOBEC3G Expression

The Efficiency of Bridging Sheet Recruitment Determines HIV-1 R5 Envelope Sensitivity to Soluble CD4 and Macrophage Tropism

Regulation of CC Chemokine Receptor 5 and CD4 Expression and Human Immunodeficiency Virus Type 1 Replication in Human Macrophages and Microglia by T Helper Type 2 Cytokines.

Low Levels of Co-Receptor CCR5 Are Sufficient to Permit HIV Envelope-Mediated Fusion with Resting CD4 T Cells.